Intellia Therapeutics, Inc. (NTLA): Results of Operations and Financial Condition

Intellia Therapeutics, Inc. (NTLA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Readying Lonvo-z forPatients with HAE November 12, 2026 Exhibit 99.1 This presentation contains “forward-looking statements” of Intellia Therapeutics, Inc. (“Intellia”, “we” or “our”) within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-lookin

Original reporting
Published Nov 12, 2026, 9:14 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 12, 2026, 9:19 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$NTLA
Neutral
medium confidence
Mentioned
$NTLA
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$NTLANeutralLow
01

Why it matters

The filing does not contain new trial outcomes, regulatory approvals, or financial metrics, limiting its immediate trading relevance.

02

Market read

Routine SEC update with no fresh data; low trading relevance.

03

What to watch

Potential hidden risk in partnership with Regeneron and manufacturing capacity not discussed in detail.

Relevance 7/10Novelty 2/10Timing: none
AlphAI · Earnings readNTLA · Not stated in filing (investor presentation dated November 12, 2026, furnished under Item 2.02)

Intellia presents Phase 3 HAELO data and launch readiness for lonvo-z in hereditary angioedema; the filing contains no financial results

→Mixed quarter

The filing is an investor presentation on clinical data, market research and launch preparation. It prints no revenue, margin, operating expense, EPS, cash or guidance figures, so financial performance cannot be assessed. The clinical and commercial figures it does print are favorable, but several are company-commissioned, pooled across phases or drawn from small subsets, and the safety table includes a Grade 3 pulmonary embolism and a serious adverse event.

Key metrics

as reported
MetricValueq/qy/y
HAELO Phase 3 patients enrolledother80 patients––
HAELO Phase 3 lonvo-z arm (n)othern=52––
HAELO Phase 3 placebo arm (n)othern=28––
Attack-rate reduction after lonvo-z vs prior LTP (HAELO subset taking LTP at enrollment, N=35)other81% reduction in attack rate––
Likelihood of complete HAE control after lonvo-z vs prior LTPother~3×––
Patients LTP-free as of latest data cutoff (pooled analysis)other100%––
Patients who received lonvo-z in Phase 1/2, Phase 3 and placebo crossover (cumulative, as printed)other117 patients––
Patients who received one lonvo-z 50 mg doseother93––
Mean duration of follow-up, lonvo-z 50 mg safety population (N=93)other7.6 months (range 0.3-46.5)––
Any treatment-emergent adverse event, lonvo-z 50 mg (N=93)other82 (88)––
Infusion-related reaction, lonvo-z 50 mg (N=93)other51 (55)––
Serious adverse events, lonvo-z 50 mg (N=93)other2 (<1%)––
Grade 3 TEAEs, lonvo-z 50 mg (N=93)other2 (<1%)––
Patients remaining in long-term follow-up (lonvo-z 50 mg)other31/32 patients––
HCPs who would prescribe lonvo-z within one year of approval (market research, n=151)other88%––
Patient preference for lonvo-z vs highest-ranked clinical-stage LTP (blinded TPP study, N=107)other2.8x––
U.S. treated HAE adults (IQVIA LAAD+ 2018-2025 population estimate)other~7,500––

What drove it

  • Company states the HAELO Phase 3 trial achieved its primary and all key secondary endpoints, with data cutoff February 10, 2026.
  • Company states that lonvo-z is designed to inactivate the KLKB1 gene and that kallikrein reduction remained deep and durable with up to 4 years of follow-up.
  • Company states that the BLA was accepted by the FDA with priority review granted and a PDUFA goal date of March 10, 2027.
  • Company states that the FDA communicated it is not currently planning to hold an advisory committee for the application (communication dated September 3, 2026).
  • Company states that a commercial team for a one-time therapy is in place, with payer outreach begun in early 2025 and ATC network building underway.
  • Company states that the lonvo-z launch preparation covers an HCP education program (digital launched May 2026, field engagement initiated September 2026).

Concerns

  • The filing contains no reported revenue, margin, earnings or cash figures, so the financial position and the cost of the launch cannot be assessed from this document.
  • Safety table (lonvo-z 50 mg, N=93): 88% of patients reported any TEAE and 55% reported infusion-related reactions; one Grade 3 pulmonary embolism occurred 12 months after infusion, which the filing says occurred in a patient with multiple risk factors.
  • The filing reports one Grade 3 perforated appendicitis 22 months after infusion, which the company states was not considered treatment-related.
  • The filing states that potential benefits depend on durability, final labeling, payer policies and pricing.
  • The company notes that prior one-time launches struggled with coverage and reimbursement timing, authorized treatment center hurdles and late hiring.
  • Several efficacy and preference figures come from a subset (N=35), pooled multi-phase data, company-commissioned research or a cross-trial comparison that the filing describes as illustrative only.

What to watch

  • FDA action on the lonvo-z BLA, PDUFA goal date March 10, 2027.
  • Final labeling, payer policies and pricing, which the filing says the benefit depends on.
  • Durability and long-term safety data as follow-up matures, including the 31/32 patients in long-term follow-up.
  • Activation of the authorized treatment center network and timing of first patient prescriptions and first revenue, shown in the company's illustrative launch timeline of months 0 to 12 that is stated to depend on approval.
  • Commercial payer coverage: the filing says most commercial lives are expected to be covered between months 6 and 9 after launch, described as illustrative and approval-dependent.

Analysis

This filing is an investor presentation furnished under Item 2.02, not an earnings release. It contains no income statement, balance sheet, cash flow statement, revenue line, earnings per share or financial guidance, so the financial performance of Intellia for the period cannot be read from it. The document's substance is clinical and commercial: Phase 3 HAELO results for lonvo-z in hereditary angioedema, pooled long-term follow-up data, market research on prescriber and patient interest, and launch preparation ahead of a PDUFA goal date of March 10, 2027.

On the clinical side, the filing states that HAELO achieved its primary and all key secondary endpoints. It prints 80 patients enrolled, with 52 in the lonvo-z arm and 28 in placebo. The company reports an 81% attack-rate reduction in a 35-patient subset that was on long-term prophylaxis at enrollment, and states that patients were about 3x more likely to have complete control after lonvo-z than with prior prophylaxis. For the pooled analysis, the filing states 100% of patients were LTP-free as of the latest data cutoff. The primary and key secondary endpoint percentages are laid out in the slide with ambiguous positioning, so this read does not assign them to a specific endpoint.

The safety data are presented as favorable and well tolerated, but the table is not silent on risk. Among 93 patients given a 50 mg dose, 82 (88) reported a treatment-emergent adverse event and 51 (55) reported an infusion-related reaction. Two serious adverse events and two Grade 3 events are printed. The filing attributes one Grade 3 pulmonary embolism to a patient with several risk factors, and describes a Grade 3 perforated appendicitis as not considered treatment-related by the company. The filing also notes that the 1:3 placebo allocation and the infusion premedication regimen are part of the protocol.

On the commercial side, the company's figures come from its own research. It reports that 88% of 151 surveyed HCPs would prescribe lonvo-z within one year of approval, and that patients in a blinded study ranked lonvo-z 2.8x higher than the top-ranked clinical-stage LTP. The company also states it has a dedicated launch team, payer outreach since early 2025 and a network of authorized treatment centers under development. The timeline for coverage and first revenue is labeled illustrative and approval-dependent, and the filing cautions that coverage decisions and site activation may take longer.

The figures most worth attention are the regulatory timeline (BLA accepted with priority review, no advisory committee planned), the safety events in the 50 mg table, and the commercial assumptions, which rest on company-commissioned research and an illustrative launch schedule. Any assessment of revenue, margin, cash runway or guidance requires the company's earnings release or financial statements, which are not in this filing.

Not in the filing

stated, not guessed
  • No income statement: total revenue, cost of sales, gross margin, R&D, SG&A and other operating expense lines, operating loss, net loss, EPS.
  • No balance sheet or cash flow figures: cash, cash equivalents, marketable securities, debt, operating cash flow, free cash flow.
  • No capital returns information (repurchases, dividends) printed.
  • No segment or product revenue lines printed; no lonvo-z revenue or sales figures.
  • No fiscal period label or period end date for financial results; the filing is dated November 12, 2026 and presents clinical and market data only.
  • No executive quotes in the presentation text that qualify as direct quotations from named speakers under the quote rule; patient and PI quotes are not used.
  • The HAELO primary and key secondary endpoint percentages (62%, 11%, 87% with CI, odds ratio 12.8) are printed in a layout where their assignment to specific endpoints and arms cannot be confirmed from the text; they are not assigned as metrics here.
  • Prior-year and prior-quarter comparisons for any figure: not printed.
  • No share price, consensus estimate or analyst expectation information in the filing.
  • The prior outlook covered milestones for the second half of 2026 and first half of 2027 and no quantitative figures that match any reported row in this release.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Background

Intellia Therapeutics filed an 8‑K reporting its operational results and forward‑looking statements for its CRISPR‑based HAE therapy, lonvo‑z.

Company-level read

Ticker impact

$NTLANeutralMedium confidence
Context

SEC Form 8‑K filing discloses Intellia Therapeutics' results of operations and forward‑looking statements on its HAE therapy.

Expected impact

likely limited movement as investors await concrete trial data or regulatory decision.

Evidence & confidence

The filing repeats known development plans and risk factors; no new approval, data, or financial numbers were introduced.

Market effects

None beyond standard biotech sector awareness of Intellia's pipeline.

No regional effect; the filing is a routine US SEC disclosure.

Minimal; no global macro or sector shift implied.

Counterpoint

Investors could view the filing as a reminder of execution risk and maintain a short bias until data materializes.

Key entities

  • Intellia Therapeutics, Inc.

    Biotech developing CRISPR‑based therapies, subject of the 8‑K filing.

  • Regeneron Pharmaceuticals, Inc.

    Partner mentioned in risk factors; no new deal disclosed.

Every NTLA earnings report

This story covers one filing. The ticker page keeps them all: each quarter's reported metrics with year-over-year and sequential comparisons, segments, guidance, and how the numbers landed against the company's own prior outlook.

Related articles

$NTLAHighAI 8/10

Intellia stock price target maintained at $30 by Citizens on HAE data

Citizens maintained a $30 price target on Intellia Therapeutics (NTLA) after positive data on its lonvo-z treatment for hereditary angioedema. The firm noted strong patient demand and key opinion leader interest, with a sum-of-the-parts analysis valuing the HAE opportunity at $20 per share. NTLA trades at $10.55 with a market cap of $1.48 billion. The FDA granted Priority Review to lonvo-z, with a potential approval date of March 10, 2027.

$NTLAMedAI 8/10

Intellia presents lonvo-z data at allergy conference

Intellia Therapeutics (NTLA) presented positive data on its hereditary angioedema treatment, lonvo-z, at a conference. The Phase 3 HAELO trial showed an 81% decrease in monthly attack rate. The Phase 1/2 study showed 100% of patients on a 50 mg dose were free from long-term prophylaxis, with 90% attack-free after one year. The FDA accepted the Biologics License Application with a target action date of March 10, 2027.

$NTLAMed

Intellia Therapeutics Announces Third Quarter 2026 Financial Results

Intellia Therapeutics, Inc. (NTLA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Intellia Therapeutics Announces Third Quarter 2026 Financial Results and Business Updates - On track to complete lonvo-z commercial readiness efforts in advance of March 10, 2027 PDUFA date - New lonvo-z patient perspectives and Phase 1/2 durability data to be includ